Pfizer’s TUKYSA regimen gets FDA approval for HER2+ metastatic breast cancer
Story updates
04:57:10 PM UTC
SquawkNews
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive…
04:57:29 PM UTC
SquawkNews
Pfizer received FDA approval for TUKYSA (tucatinib) with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable locally advanced or metastatic HER2+ breast cancer following induction treatment.Material DetailsContext by AI AnalystThis is a label expansion that advances an…
05:14:39 PM UTC
SquawkNews
By Katherine HamiltonPfizer said the Food and Drug Administration approved Tukysa as a front-line maintenance treatment for people with a form of breast cancer.Tukysa was approved in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanc…